Summit Therapeutics Inc. cotiza a 17.59 USD y tiene una capitalización bursátil de $14.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angio…
| Periodo | 2026-10 | 2026-07 | 2026-04 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.21 | $-0.18 | $-0.21 |
| Estimado | $-0.21 | $-0.21 | $-0.21 | $-0.01 |
| Sorpresa | — | +0.0% | +14.3% | -2000.0% |
| Métrica | SMMT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -163.9% | -40.4% | -123.5% |
| ROA | -143.7% | -32.0% | -111.7% |
| Current Ratio | 9.87 | 2.84 | +7.03 |
| Debt / Equity | — | 0.28 | — |